CN1265660A - 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives - Google Patents

2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives Download PDF

Info

Publication number
CN1265660A
CN1265660A CN98807831A CN98807831A CN1265660A CN 1265660 A CN1265660 A CN 1265660A CN 98807831 A CN98807831 A CN 98807831A CN 98807831 A CN98807831 A CN 98807831A CN 1265660 A CN1265660 A CN 1265660A
Authority
CN
China
Prior art keywords
piperazine
fluoro
disorder
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98807831A
Other languages
Chinese (zh)
Inventor
安东·F·J·弗里利
马克·J·马吉科扎克
帕特里西亚·A·西摩
史蒂文·H·佐恩
汉斯·罗尔马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1265660A publication Critical patent/CN1265660A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

A compound of the formula (I) wherein T, V, X, Y, Z, R<1>, R<2>, R<3>, R<4>, R<5>, R<6>, R<7>, R<8> and R<9> are as defined above, their pharmaceutically acceptable salts and pharmaceutical compositions containing such compounds or their salts.

Description

2-(4-aryl or heteroaryl-piperazine-1-ylmethyl)-1H-indole derivatives
Background of invention
The present invention relates to have central dopamine can active 2-(4-aryl or heteroaryl-piperazine-1-ylmethyl)-1H-indole derivatives.These compounds can be used for treating central nervous system (CNS) disorder.The invention still further relates to and use the particularly method of human above-mentioned disorder of these compounds for treating Mammalss, and relate to the medicinal compositions that is used for its purposes.
Common known Dopamine Receptors is very important for many functions of animal body.For example, the variation function of these acceptors participates in taking place psychosis, dopy, mandatory disorder, existing manic emotionality disorder, photis, vomiting, sleep, nursing, study, memory, sexual function, the adjusting of immune induced and the blood pressure that paralepsy is arranged again.Because these acceptors are controlled a large amount of pharmacology mechanism, and now its mechanism is not all understood, thereby possible preferential interaction can be to human relevant general result of treatment at the compound of D4 Dopamine Receptors.
2-of the present invention (4-aryl or heteroaryl-piperazine-1-ylmethyl)-1H-indole derivatives, the pattern that comprises tautomer, enantiomer and acceptable acid additive salt, it is a central action D4-dopamine-receptor stimulant, therefore can be used as identification enhanser and treatment CNS disease, unusual as Parkinson's disease, Alzheimer's, learning and memory.Another feature of the present invention provides compound of the present invention and D1, D2, D3 or D5 combination of dopamine agonists (as L-DOPA and the D2 agonist) purposes in treatment CNS disease (unusual as Parkinson's disease, Alzheimer's, learning and memory).
Summary of the invention
The present invention relates to the compound of following formula:
Or the acceptable salt of its medicine, wherein dotted line is represented a selectable pair of key;
A is 0 or 1, and wherein when a was 0, X formed optional two keys with the carbon of adjacency V;
V is CHR 10, R wherein 10Be hydrogen or (C 1-C 6) alkyl;
T is nitrogen or CH;
X is nitrogen or CR 11, R wherein 11Be hydrogen, (C 1-C 6) alkyl, (C 1-C 6) alkoxyl group, hydroxyl itself or cyano group;
Each is nitrogen or CR independently for Y and Z 12, R wherein 12Be hydrogen, chlorine, bromine, trifluoromethyl, trifluoromethoxy, cyano group, (C 1-C 6) alkoxyl group or (C 1-C 6) alkyl;
R 1Be hydrogen, fluorine, chlorine, bromine, trifluoromethyl, trifluoromethoxy, cyano group, or (C 1-C 6) alkyl;
R 2, R 6, R 7, R 8And R 9Be independently selected from hydrogen, fluorine, chlorine, bromine, trifluoromethyl, trifluoromethoxy, cyano group, (C 1-C 6) alkoxyl group or (C 1-C 6) alkyl;
R 3And R 4Be hydrogen or (C independently 1-C 6) alkyl; With
R 5Be hydrogen, (C 1-C 6) alkoxyl group, trifluoromethyl, cyano group, (C 1-C 6) alkyl or R 13CO-, wherein R 13Be amino, (C 1-C 6) alkylamino, ((C 1-C 6) alkyl) 2Amino, (C 1-C 6) alkyl, (C 1-C 6) aryl;
Or when a is 1, R 1And R 10Carbon that can be coupled forms the compound of following formula together: Wherein dotted line is represented a selectable key; T, X, Y, Z, R 2, R 3, R 4, R 5, R 6, R 7, R 8And R 9Definition as above; B is 0 or 1; Each is CH independently with A and B, CH 2, oxygen, sulphur, NH or nitrogen; Condition is when X is nitrogen, does not have optional two keys between X and the V; With condition be when b is 0, do not have optional two keys between A and the B; With
Condition is when b is 1, and A and B can not be oxygen or sulphur.
Term used herein " alkyl ", except as otherwise noted, comprise have straight chain, the saturated univalence hydrocarbyl of side chain and circular part or its combination.
Term used herein " alkoxyl group " comprises the O-alkyl, and wherein " alkyl " definition as above.
Term used herein " treatment " refers to reverse, alleviate, suppress the disorder of this term indication or symptom or these disorders or symptom one or more symptoms development or prevent its generation.
Term used herein " treatment " refers to therapeutic action, and " treatment " defines as above.
Term used herein " disorder of Dopamine HCL system " refers to by the neurotransmission that changes (promptly increase or reduce) Dopamine HCL mediation can influence or alleviate disorder to its treatment.
Therefore be dopamine receptor subtype, be in particular the The compounds of this invention of dopamine d 4 receptor part, be used for the treatment of the disorder of Dopamine HCL system in vivo.
Formula I compound can have chiral centre, thereby has different enantiomorph patterns.The invention still further relates to all optical isomers and steric isomer and its mixture of formula I compound.
The preferred compound of formula I comprises that wherein X is a nitrogen compound.
Other preferred compound of formula I comprises wherein Y and Z, and each is CR 12Compound, R wherein 12Be hydrogen or fluorine.
Other preferred compound of formula I comprises wherein R 2It is the compound of hydrogen, fluorine or chlorine.
Other preferred compound of formula I comprises wherein R 3, R 4And R 5It is the compound of hydrogen.
Other preferred compound of formula I comprises wherein R 7It is the compound of fluorine or chlorine.
Other preferred compound of formula I comprises wherein R 9It is the compound of fluorine, chlorine, bromine or alkoxyl group.
The more preferably compound of formula I compound comprises that wherein X is a nitrogen; Each is CR for Y and Z 13Compound, R wherein 13Be hydrogen or fluorine; R 2Be hydrogen, fluorine or chlorine; R 3, R 4And R 5Be hydrogen; R 7It is fluorine or chlorine; R 9It is the compound of fluorine, chlorine, bromine or alkoxyl group.
The particularly preferred compound of formula I comprises following compound:
2-[4-(3-trifluoromethyl-phenyl)-piperazine-1-ylmethyl]-the 1H-indoles;
5-fluoro-2-[4-(3-trifluoromethyl-phenyl)-piperazine-1-ylmethyl]-the 1H-indoles;
5-fluoro-2-[4-(4-methyl fluoride-phenyl)-piperazine-1-ylmethyl]-the 1H-indoles;
5-fluoro-2-[4-(4-methyl fluoride-phenyl)-piperazine-1-ylmethyl]-the 1H-indoles;
5-fluoro-2-(4-pyridine-2-base-piperazine-1-ylmethyl]-the 1H-indoles;
2-[4-(6-chloro-pyridazine-3-yl)-piperazine-1-ylmethyl]-5-fluoro-1H-indoles;
5-fluoro-2-(4-[5 '-fluorine] pyridine-2-base-piperazine-1-ylmethyl]-the 1H-indoles;
2-(4-pyridine-2-base-piperazine-1-ylmethyl)-1H-indoles;
5-fluoro-2-(4-pyridine-2-base-piperazine-1-ylmethyl]-the 1H-azaindole; With
2-[4-(4-fluoro-phenyl)-piperazine-1-ylmethyl]-the 1H-azaindole.
The invention still further relates to the method for treatment Mammals disorders of dopamine system, this disorders of dopamine system comprises psychosis (alternating insanity, incoherence of speech and schizoaffective psychosis), mobility disorder (the extrapyramidal side effect that tranquilizer produces, the pernicious syndromes of tranquilizer, tardy dyskinesia, the Tourette's syndrome syndromes, Parkinson's disease, Huntington), gastrointestinal dysfunction (hydrochloric acid in gastric juice secretin or vomiting), chemical abuse disease, the chemical dependence syndrome, substance abuse disease, blood vessel and cardiovascular disorder (congestive heart failure and hypertension), eyes are disorderly and sleep disordered, and this method comprises gives said Mammals with the D4 dopamine 2 receptor alternative cpd or the acceptable salt dispenser of its medicine of effectively treating a certain amount of formula I of this disorder.
The invention still further relates to the method for treatment Mammals disorders of dopamine system, this disorders of dopamine system comprises psychosis (alternating insanity, incoherence of speech and schizoaffective psychosis), mobility disorder (the extrapyramidal side effect that tranquilizer produces, the pernicious syndromes of tranquilizer, tardy dyskinesia, the Tourette's syndrome syndromes, Parkinson's disease, Huntington), gastrointestinal dysfunction (hydrochloric acid in gastric juice secretin or vomiting), chemical abuse disease, the chemical dependence syndrome, substance abuse disease, blood vessel and cardiovascular disorder (congestive heart failure and hypertension), eyes are disorderly and sleep disordered, this method comprises and will effectively treat D4 dopamine 2 receptor alternative cpd or the acceptable salt of its medicine of a certain amount of formula I of this disorder, in conjunction with one or more D1, D2, D3 or D5 dopamine-receptor stimulant dispenser together give said Mammals.
The invention still further relates to the pharmaceutical composition of treatment Mammals disorders of dopamine system, this disorders of dopamine system comprises psychosis (alternating insanity, incoherence of speech and schizoaffective psychosis), mobility disorder (the extrapyramidal side effect that tranquilizer produces, the pernicious syndromes of tranquilizer, tardy dyskinesia, the Tourette's syndrome syndromes, Parkinson's disease, Huntington), gastrointestinal dysfunction (hydrochloric acid in gastric juice secretin or vomiting), chemical abuse disease, the chemical dependence syndrome, substance abuse disease, blood vessel and cardiovascular disorder (congestive heart failure and hypertension), eyes are disorderly and sleep disordered, this methods of treatment comprises and will effectively treat D4 dopamine 2 receptor alternative cpd or the acceptable salt of its medicine of a certain amount of formula I of this disorder, in conjunction with one or more D1, D2, D3 or D5 dopamine-receptor stimulant dispenser together give said Mammals.
Detailed Description Of The Invention
The preparation of following reaction process explanation The compounds of this invention.Except as otherwise noted, a, T, V, X, Y, Z, R in reaction process and the following discussion 1, R 2, R 3, R 4, R 5, R 6, R 7, R 8And R 9Definition as above.
Flow process 1 Flow process 2
In the reaction 1 of flow process 1, at first in polar aprotic solvent such as methylene dichloride, use O-, N-dimethyl oxammonium hydrochloride, dicyclohexyl carbodiimide and alkali such as triethylamine are handled III, make the compound coupling of formula III and IV form the respective compound of formula I.At the azanol intermediate of polar aprotic solvent as forming as the lithium aluminium hydride reduction with reductive agent in the tetrahydrofuran (THF).Aldehyde and formula IV compound reaction in polar aprotic solvent such as ethylene dichloride in the presence of the triacetyl sodium borohydride is carried out reduction amination to the aldehyde intermediate of formation like this.Under inert atmosphere room temperature, stirred this reaction mixture about 40 hours-Yue 56 hours, preferred about 48 hours.
In the reaction 1 of flow process 2, at diisopropylethylamine, carbodiimide or dewatering agent exist down, in polar aprotic solvent such as methylene dichloride, or if need, the form of mixtures that is the combination that contains organic solvent or water, as ring and acyclic list and dialkyl amide, (C1-C4) alcohol, halogenated solvent, or combination acyclic or ring pass alkyl oxide, at about 0 ℃-Yue 150 ℃, under the boiling point of preferred about 0 ℃ or same solvent mixture, VI and IV react corresponding ketone (methanone) compound that just formula VI compound and IV coupling form formula III, and L is leavings group such as chlorine among the formula VI, bromine, methoxyl group or any activatory ester derivative such as p-nitrophenyl ester, oxybenzene and triazole ester, N-hydroxy-succinamide ester or hydroxyl.The acceptor of acid such as the addition of basic carbonate, tertiary amine or similar reagents are useful.
In the reaction 2 of flow process 2, in polar aprotic solvent such as tetrahydrofuran (THF), use reductive agent such as lithium aluminium hydride or boron derivative reduction V about 7 hours-Yue 14 hours, preferred about 12 hours, the methanone compounds of wushu V transformed the respective compound of accepted way of doing sth I, and wherein R3 and R4 are hydrogen.
In each above-mentioned reaction, pressure is not conclusive.About 0.5-3 atmospheric pressure suits, and normal pressure (about 1 normal atmosphere usually) is preferably pressure easily.In addition, for those reactions that preferred temperature wherein changes along with the particular compound of reaction, do not enumerate preferred temperature.For these reactions, can use thin-layer chromatography to monitor this and react the preferred temperature of measuring concrete reagent.
The new compound of formula I and the acceptable salt of its medicine (this paper " treatment compound of the present invention ") can be used as Dopamine HCL reagent, and promptly it has the ability that Mammals comprises the neurotransmission of human Dopamine HCL mediation that changes.Therefore, it can be as the therapeutical agent of treatment Mammals various diseases, this treatment or prevent from can to influence or alleviate by the neurotransmission that increases or reduce the Dopamine HCL mediation.
The formula I compound that is alkalescence can form various salt with various mineral acids and organic acid.Though these salt must be that medicine is acceptable to giving the Mammals administration, but usually wish that in fact initial gross separation formula I compound is as the acceptable salt of medicine from reaction mixture, by handling latter's simple conversion is returned the free basic cpd then, again the latter's free alkali is converted into the acceptable acid salt of medicine with alkaline reagents.By in water solvent medium or suitable organic solvent such as methyl alcohol or ethanol, handling this basic cpd, be easy to prepare the acid salt of basic cpd of the present invention with the selected inorganic or organic acid of equivalent in fact.Also can from the solution of this free alkali, precipitate required acid salt by in this solution, adding suitable inorganic or organic acid.
Treatment compound of the present invention can be oral, through skin (as using patch), parenteral or topical.The preferred oral administration.Usually wish most these compounds with every day about 0.1mg to the highest about 1000mg, or at the dosed administration of more every situation following every day of 1mg-1000mg, but but the patient's that the root a tree name is treated the body weight and the disease heart and selected concrete route of administration and changed.In some cases, the dosage that is lower than the lower limit of above-mentioned scope can be preferably, and in other cases, can use not cause the more heavy dose of of any harmful side effect, and condition is several low doses that these heavy doses at first are divided into a whole day dispenser.
Treatment compound of the present invention is can be by any of above-mentioned two kinds of approach individually dosed or with other pharmaceutical carrier or thinner administration, administration can single dose or multiple doses.More specifically, the new treatment compound of the present invention can various formulations be convenient to administration, promptly combines with tablet, capsule, lozenge, lozenge, hard candy, pulvis, spraying, emulsifiable paste, ointment, suppository, gelifying agent, frozen glue, paste, lotion, ointment, elixir, syrup etc. with various pharmaceutical carriers.Suitable pharmaceutical carrier for example comprises inert solid diluent or filler, aseptic aqueous solution and various organic solvent.In addition, suitably dulcification and/or flavoring of composition for oral liquid.
For oral, the tablet that contains various vehicle such as Microcrystalline Cellulose, Trisodium Citrate, lime carbonate, secondary calcium phosphate and glycine can use with various disintegrating agents such as starch (and being preferably corn, potato or tapioca (flour)), alginic acid and some composition silicate, and uses with granulation binders such as polyvinylpyrrolidone, sucrose, gelatin and gum arabic.In addition, lubricant such as Magnesium Stearate, sodium lauryl sulphate and talcum powder are also through being usually used in tablet.The solids composition of similar model also can be used as filler in the gelatine capsule of soft and rigid filling.Its preferred material comprises lactose or caramel and high-molecular weight polyoxyethylene glycol.When oral when needing waterborne suspension or elixir, necessary active constituent of the present invention can with various sweeting agents or correctives, tinting material or dyestuff, if necessary, emulsifying agent or suspension agent and thinner such as water, ethanol, propylene glycol, glycerine and the combination together of its mixture.
Through enteral administration, can use the solution of The compounds of this invention in sesame or peanut oil or aqueous solution of propylene glycol for non-.If desired, these aqueous solution should suitably be cushioned, and this liquid diluent at first with make its etc. ooze.These aqueous solution are suitable for intravenously, intramuscular, subcutaneous and intraperitoneal administration.The known standard method of the available those skilled in the art of the preparation of all these solution under aseptic condition and be easy to carry out.
In addition, when treatment during skin inflammation, but also topical of The compounds of this invention, but the pharmacy practice of its root a tree name standard is preferably undertaken by emulsifiable paste, gelifying agent, gel, paste, ointment etc.
With following method measure compound be attached to ability and The compounds of this invention on the Mammals Dopamine Receptors suppress [ 3H]-Spiperone is attached to the relative capacity on people's dopamine d 4 receptor subclass of expressing in cloned cell line.
The binding ability of D4 acceptor
People such as Van Tol have introduced the mensuration (Nature, 1991,350,610) of D4 receptor binding capacity.Containing 5mM EDTA, 1.5mM calcium chloride (CaCl2), 5mM magnesium chloride (MgCl2), the 50mM Tris of 5mM Repone K (KCl) and 120mM sodium-chlor (NaCl); Collection and homogenizing are expressed the clone cell of human dopamine d 4 receptor among the HCl (pH7.4 in the time of 4 ℃).48, under the 000g centrifugal homogenate 10-15 minute, and a granular substance that obtains is suspended in the buffer reagent that concentration is 150-250mG/ml.About saturation experiments, cumulative volume is 1ml, under 22 ℃, with concentration increase progressively [ 3H]-spiperone (70.3Ci/mmol; The 10-3000 ultimate density) cultivated the 0.75ml aliquot of tissue in triplicate 30-120 minute.About competition combination test, add the 0.75ml film also with the competition part (10 of indicating concentration -14-10 -13M) and/or [ 3H]-spiperone (100-300pM) cultivated 60-120 minute down at 22 ℃ in duplicate, began assessment.The tritium that filters, monitors then filtrate by the Brandell cell harvestor fast finishes assessment, as Sunahara, and people such as R.K. (Nature, 1990,346,76).For all experiments, specific [ 3H]-spiperone is in conjunction with being defined as the inhibition that is produced by 1-10mM (+) butaclamol.With nonlinear least square curve fitting analysis binding data.With the compound of this appraisal procedure test implementation example, all find to have less than 2 micromolar [ 3H]-the spiperone metathetical is in conjunction with affinity (Ki).
The human body D4 acceptor that cAMP forms is regulated
From Dr.H.Van Tol (Clarke Institute of Psychiatry, Toronto) obtain expressing Chinese hamster ovary (CHO) cell of human D4.4 Dopamine Receptors, and growth is paved with in the additional Minimal Essential Alpha Media (Gibco) of serum (not having hot deactivation), 2.5% horse serum (hot deactivation) and the 500 μ/ml Geneticin of 2.5% tire ox.Break unimolecular layer, make cell deposition with 5mM ethylenediamine tetraacetic acid (EDTA) (EDTA), and be suspended in once more in the physiological saline of the phosphate buffered that contains 5mM magnesium chloride, 30mM hydroxyethyl piperazine-N-ethylsulfonic acid (HEPES), 300 μ M3-isobutyl--1-methyl-xanthine (IBMX, phosphodiesterase inhibitor) and 5.6mM glucose.Cell (about 200,000/ pipe) is exposed to 5 μ M forskolins (forskolin) (adenylate cyclase enzyme activator), forskolin to be added test compound or quinpirole (D4 receptor stimulant) or forskolin and adds quinpirole and add in the antagonist 11 minutes.In the experiment of useful antagonist, before agonist is handled, cellular exposure in antagonist 11 minutes.Estimate the activity of agonist with the effect of the test compound that does not have agonist quinpirole.The D4 agonist has produced the cAMP accumulation to be suppressed, and it can reverse by the D4 receptor antagonist.Add 6N and cross the chloric acid termination reaction, and with in 5N potassium hydroxide and the 2M Tris buffer reagent and sample.Measure ring-type AMP amount with the competition binding reagents box (Amersham) that is purchased.IC is calculated in linear regression analysis by concentration-response curve 50Value.Use equation: Ki=IC 50/ (the 1+[antagonist]/[agonist EC 50]) (Minneman and Johnson, 1984) calculating K i value.
The present invention illustrates the present invention with the following example, but is not limited to its details.Embodiment 1
2-[4-(6-chloro-piperazine-3-yl)-piperazine-1-ylmethyl]-5-fluoro-1H-indoles
At room temperature stir 5mg 5-fluorine 2 indole-carboxylic acids, 2.74mg O-, N-dimethyl oxammonium hydrochloride, 3.89ml triethylamine and 5.76mg dicyclohexyl carbodiimide mixture in the 35ml methylene dichloride is until forming the tawny precipitation.The solids removed by filtration thing, concentration residue and at SiO 2(25%EtOAc is in hexane) goes up purifying.Obtain 3.6mg (64%) N-O-dimethyl 2 indoles azanols.
In 5 minutes, 3.9mg N-O-two-methyl 2 indoles azanols are joined 0.67mgLiAlH4 in the cold suspension (40 ℃) of 30ml tetrahydrofuran (THF).Stir the mixture of handling with the sodium sulfate saturated aqueous solution 1 hour (40 ℃-＞-30 ℃) and be warmed to room temperature.Separate solvent and be concentrated into formation brown precipitation (2.94mg 5-fluorine 2 indoles carboxylic aldehyde) after adding solid sodium sulfate.
Stirring 0.96mg 4-(5-chloro-phenyl)-piperazine, 1.0mg 5-fluorine 2 indoles carboxylic aldehyde and the solution of 1.2mg triacetyl sodium borohydride in the 50ml ethylene dichloride under the nitrogen room temperature.Except that desolvating and resistates being distributed among 100mlEtOAc and the 20mlNaOH (1N).(2 * 20ml) water and salt water washing organic layer also concentrate water.Resistates is at SiO 2(eluent: 5% methyl alcohol is in methylene dichloride) gone up purifying and obtained the coloured solid of white shape, its mp.:204-205 ℃.Embodiment 2
5-fluoro-1H-indoles-2-base-[4-(3-trifluoromethyl-phenyl)-piperazine-1-yl]-ketone (methone)
1.0mmol 5-fluorine, 2-indole-carboxylic acid muriate and 230mg m-trifluoromethyl phenylpiperazine and the 129mg diisopropylethylamine mixture in the 10ml methylene dichloride kept at room temperature 12 hours.Add entry, separate organic layer, wash with water, dry and concentrate on sodium sulfate, obtain the title compound of 296mg.MP：198℃。Embodiment 3
5-fluoro-2-[4-(3-trifluoromethyl-phenyl)-piperazine-1-ylmethyl]
-1H-indole hydrochloride
275mg 5-fluoro-1H-indoles-2-base-[4-(3-trifluoromethyl-phenyl)-piperazine-1-yl]-ketone is remained in the inert atmosphere at the solution of anhydrous tetrahydro furan, and at room temperature use the solution-treated of the 1M lithium aluminium hydride of 2.11ml at tetrahydrofuran (THF).After 12 hours, this mixture is with 78 μ l, 15% sodium hydroxide solution and other 234 μ l water treatments.After adding lithium aluminium hydride, separate organic layer and concentrate obtaining yellow oil (240mg).This oil is dissolved in the ether and with the ethereal solution of hydrochloric acid and handles to forming precipitation.Collecting precipitation, vacuum-drying.
The title compound for preparing embodiment 4-by the method that is similar to embodiment 1-3.Embodiment 4
2-[4-(3-trifluoromethyl-phenyl)-piperazine-1-ylmethyl]-1H-indoles-5-alcohol
MP：188-190℃；HRSMS375.15。Embodiment 5
2-[4-(3-trifluoromethyl-phenyl)-piperazine-1-ylmethyl]-the 1H-indoles
MP：192-194℃；HRSMS359.15。Embodiment 6
(1H-indoles-2-yl)-[4-(2-nitro-phenyl)-piperazine-1-yl]-ketone
MP：186-189℃。Embodiment 7
(5-fluoro-1H-indoles-2-yl)-[4-(2-nitro-phenyl)-piperazine-1-yl]-ketone
MP：184-188℃。Embodiment 8
(5-fluoro-1H-indoles-2-yl)-[4-(3-trifluoromethyl-phenyl)-piperazine-1-yl]-ketone MP:198 ℃.Embodiment 9
3-[4-(1H-indoles-2-ylmethyl)-piperazine-1-yl]-benzo [d] isothiazole
MP：150-152℃；HRSMS348.12。Embodiment 10
5-fluoro-2-[4-(3-trifluoromethyl-phenyl)-piperazine-1-ylmethyl]-the 1H-indoles
MP：196-197℃；HRSMS377.148。Embodiment 11
2-(4-naphthalene-1-base-piperazine-1-ylmethyl)-1H-indoles
MP：238-239℃；HRSMS341.19。Embodiment 12
2-[4-(2-nitro-phenyl)-piperazine-1-ylmethyl]-the 1H-indoles
MP：210-211℃；HRSMS336.16。Embodiment 13
5-fluoro-2-[4-(2-nitro-phenyl)-piperazine-1-ylmethyl]-the 1H-indoles
MP：236℃；HRSMS354.14。Embodiment 14
5-fluoro-2-(4-naphthalene-1-base-piperazine-1-ylmethyl)-1H-indoles
MP：249-250℃；HRSMS359.18。Embodiment 15
5-fluoro-2-(4-pyridine-2-base-piperazine-1-ylmethyl)-1H-indoles
MP：242℃；HRSMS310.15。Embodiment 16
5-fluoro-2-[4-(4-fluoro-phenyl)-piperazine-1-ylmethyl]-the 1H-indoles
MP: embodiment 17
5-fluoro-2-(4-pyrimidine-2-base-piperazine-1-ylmethyl)-1H-indoles
MP：199℃；HRSMS311.16。Embodiment 18
(5-fluoro-1H-indoles-2-yl)-(4-pyridine-2-base-piperazine-1-yl)-ketone
MP：214-218℃。Embodiment 19
2-(4-pyridine-2-base-piperazine-1-ylmethyl)-1H-indoles
MP: embodiment 20
(1H-indoles-2-yl)-(4-pyridine-2-base-piperazine-1-yl)-ketone
MP：198-200℃。Embodiment 21
2-(4-pyridine-2-base-piperazine-1-ylmethyl)-1H-indoles
13C?NMR(CDCl 3，75MHz)d?45.29，53.03，55.96，77.44，101.94，107.29，110.91，113.52，119.70，120.28，121.69，128.40，135.53，136.37，137.61，148.00，159.55.
1H?NMR(CDCl 3，250MHz)d?2.6(m，4H)，3.6(m，4H)，3.7(s，2H)，6.4(s，1H)，6.7(m，2H)，7.1-7.6(m，4H)，8.2(m，1H)，8.7(br.s，1H).
GC-MS, t R=4.468min., M +=292, (M-162)=130. embodiment 22
(2 ' α, 3 ' α β, 6 ' α β)-1-(4-fluoro-phenyl)-4-(5 '-phenyl-1 ', 2 ', 3 ', 3 ' a, 4 ', 6 ' a '-six hydrogen-pentalene-2 '-yl)-piperazine dihydrochloride
MP:250-253 ℃. calculated value C 24H 27FN 22HCl0.75H 2O:C, 66.28; H, 7.07; N, 6.44. measured value C, 66.18; H, 6.76; N, 6.56. embodiment 23
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-5 '-[4-(4-fluoro-phenyl)-piperazine-1-yl]-2 '-phenyl-octahydro-pentalene-2 '-pure maleic acid salt
MP:206-207.5 ℃. calculated value C 24H 29FN 2O0.75C 4H 4O 40.75H 2O:C, 67.41; H, 7.02; N, 5.82. measured value C, 67.24; H, 6.77; N, 5.68. embodiment 24
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-1-[4-(4-fluoro-phenyl)-4-(5 '-phenyl-six hydrogen-pentalene-2 '-yl)-piperazine dihydrochloride
MP:255-256.5 ℃. calculated value C 24H 29FN 22HCl0.25H 2O:C, 65.23; H, 7.18; N, 6.34. measured value C, 65.40; H, 7.02; N, 6.38. embodiment 25
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-[4-(5 '-hydroxyl-5 '-phenyl-octahydro-pentalene-2 '-yl)-piperazine-1-yl)-the benzonitrile maleic acid salt
MP:207-207.5 ℃. calculated value C 25H 28FN 3OC 4H 4O 4: C, 66.78; H, 6.18; N, 8.06. measured value C, 66.64; H, 6.06; N, 8.14. embodiment 26
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-[4-(3 ', 3 ' a, 4 ', 5 ', 6 ', 6 ' a '-six hydrogen spiral [isobenzofuran-1 (3H), 2 ' (1 ' H)-pentalene]-5 '-yl)-the 1-piperazinyl]-the benzonitrile maleic acid salt
MP:221-221.5 ℃. calculated value C 26H 28FN 3OC 4H 4O 40.5H 2O:C, 66.41; H, 6.13; N, 7.74. measured value C, 66.33; H, 6.26; N, 7.61. embodiment 27
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-5 '-[4-(2-methoxyl group-phenyl)-piperazine-1-yl]-2 '-phenyl-octahydro-pentalene-2 '-pure maleic acid salt
MP:188-189 ℃. calculated value C 25H 32N 2O 2C 4H 4O 4: C, 68.48; H, 7.13; N, 5.51. measured value C, 68.64; H, 7.10; N, 5.81. embodiment 28
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-(4-fluoro-phenyl)-5 '-[4-(5-fluoro-pyrimidine-2-base)-piperazine-1-yl]-octahydro-pentalene-2 '-pure maleic acid salt
MP:219.5-220 ℃. calculated value C 22H 26F 2N 4OC 4H 4O 40.5H 2O:C, 59.41; H, 5.94; N, 10.66. measured value C, 59.76; H, 5.89; N, 10.65. embodiment 29
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-{4-[5 '-(4-fluoro-phenyl)-5 '-hydroxyl-octahydro-pentalene-2 '-yl]-piperazine-1-yl }-the benzonitrile maleic acid salt
MP:204-204.5 ℃. calculated value C 25H 27F 2N 3OC 4H 4O 4H 2O:C, 62.47; H, 5.97; N, 7.54. measured value C, 62.77; H, 5.74; N, 7.58. embodiment 30
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2 '-(4-fluoro-phenyl)-5 '-[4-(4-fluoro-phenyl)-piperazine-1-yl]-octahydro-pentalene-2 '-pure maleic acid salt
MP:209-209.5C. calculated value C 24H 28F 2N 2OC 4H 4O 4: C, 65.36; H, 6.27; N, 5.54. measured value C, 65.65; H, 6.25; N, 5.34. embodiment 31
(2 ' α, 3 ' α β, 6 ' α β)-5-fluoro-2-[4-[5 '-phenyl-1 ', 2 ', 3 ', 3 ' a, 4 ', 6 ' a '-six hydrogen-pentalene-2 '-yl)-piperazine-1-yl }-the pyrimidine maleic acid salt
MP:202-203 ℃. calculated value C 22H 25FN 4C 4H 4O 4: C, 64.99; H, 6.08; N, 11.66. measured value C, 64.67; H, 6.00; N, 11.79. embodiment 32
(2 ' α, 3 ' α β, 6 ' α β)-2-fluoro-4-[4-[5 '-phenyl-1 ', 2 ', 3 ', 3 ' a, 4 ', 6 ' a '-six hydrogen-pentalene-2 '-yl)-piperazine-1-yl }-the benzonitrile maleic acid salt
MP:172-173 ℃. calculated value C 25H 26FN 3C 4H 4O 4: C, 69.17; H, 6.00; N, 8.34. measured value C, 69.06; H, 5.88; N, 8.57. embodiment 33
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-5-fluoro-2-[4-[5 '-phenyl-octahydro-pentalene-2 '-yl)-piperazine-1-yl]-the pyrimidine maleic acid salt
MP:211.5-212 ℃. calculated value C 22H 27FN 4C 4H 4O 4: C, 64.72; H, 6.48; N, 11.61. measured value C, 64.67; H, 6.43; N, 11.82. embodiment 34
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-[4-[5 '-phenyl-octahydro-pentalene-2 '-yl)-piperazine-1-yl]-the benzonitrile maleic acid salt
MP:195-196 ℃. calculated value C 25H 28FN 3C 4H 4O 4: C, 68.89; H, 6.38; N, 8.31. measured value C, 68.99; H, 6.47; N, 8.30. embodiment 35
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-{4-[5 '-trifluoromethyl-phenyl)-octahydro-pentalene-2 '-yl]-piperazine-1-yl }-the benzonitrile maleic acid salt
MP:192-193 ℃. calculated value C 26H 27F 4N 3C 4H 4O 4: C, 62.82; H, 5.45; N7.33. measured value C, 62.87; H, 5.22; N, 7.27. embodiment 36
(2 ' α, 3 ' α β, 6 ' α β)-2-fluoro-4-{4-[5-(2-methoxyl group-phenyl)-1 ', 2 ', 3 ', 3 ' a, 4 ', 6 ' a '-six hydrogen-pentalene-2 '-yl)-piperazine-1-yl }-the benzonitrile maleic acid salt
MP:155-156 ℃. calculated value C 26H 28FN 3OC 4H 4O 40.25H 2O:C, 66.96; H, 6.09; N, 7.81. measured value C, 67.00; H, 6.05; N, 7.82. embodiment 37
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-{4-[5 '-(2-methoxyl group-phenyl)-octahydro-pentalene-2 '-yl)-piperazine-1-yl }-the benzonitrile maleic acid salt
MP:176-177 ℃. calculated value C 26H 30FN 3OC 4H 4O 40.50H 2O:C, 66.16; H, 6.48; N, 7.71. measured value C, 66.20; H, 6.31; N, 7.69. embodiment 38
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-{4-[5 '-(1H-indol-3-yl)-octahydro-pentalene-2 '-yl)-piperazine-1-yl }-the benzonitrile maleic acid salt
MP:226-227 ℃. calculated value C 27H 29FN 4C 4H 4O 4: C, 68.37; H, 6.11; N, 10.29. measured value C, 68.17; H, 6.24; N, 10.20. embodiment 39
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-{4-[5 '-(2-methylsulfonyl-phenyl)-octahydro-pentalene-2 '-yl)-piperazine-1-yl }-the benzonitrile maleic acid salt
MP:179-180 ℃. calculated value C 26H 30FN 3O 2SC 4H 4O 40.25H 2O:C, 61.25; H, 5.91; N, 7.14. measured value C, 61.26; H, 6.32; N, 6.76. embodiment 40
(2 ' α, 3 ' α β, 5 ' β, 6 ' α β)-2-fluoro-4-[4-(3 ', 3 ' a, 4 ', 5 ', 6 ', 6 ' a '-six hydrogen spiral [isobenzofuran-1 (3H), 2 ' (1 ' H)-pentalene]-5 '-yl)-the 1-piperazinyl]-the benzonitrile maleic acid salt
MP＞260 ℃. calculated value C 26H 28FN 3OCH 4O 3S:C, 63.14; H, 6.27; N, 8.18. measured value C, 63.12; H, 6.66; N, 8.00. embodiment 41
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-[4-(3 ', 3 ' a, 4 ', 5 ', 6 ', 6 ' a '-six hydrogen spiral [2H-1-cumarone-2,2 ' (1 ' H)-pentalene]-5 '-yl)-the 1-piperazinyl]-the benzonitrile maleic acid salt
MP:176-177 ℃. calculated value C 27H 28FN 3O 2C 4H 4O 40.50H 2O:C, 65.25; H, 5.82; N, 7.36. measured value C, 65.52; H, 6.06; N, 7.19. embodiment 42
(2 ' α, 3 ' α β, 5 ' β, 6 ' α β)-2-fluoro-4-[4-(3,3 ', 3 ' a, 4,4 ', 5 ', 6 ', 6 ' a '-six hydrogen spiral [2H-1-cumarone-2,2 ' (1 ' H)-pentalene]-5 '-yl)-the 1-piperazinyl]-the benzonitrile maleic acid salt
MP:179-180 ℃ of calculated value C 27H 28FN 3O 2C 4H 4O 4: C, 66.30; H, 5.74; N, 7.48. measured value C, 66.17; H, 6.07; N, 7.34. embodiment 43
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-{4-[5 '-(2-trifluoromethoxy-phenyl)-octahydro-pentalene-2 '-yl)-piperazine-1-yl }-the benzonitrile maleic acid salt
MP:126-129 ℃ of .NMR DMSO d 6δ 7.70 (t, J=8.5Hz, 1H), 7.52 (d, J=7.1Hz, 1H), and 7.40-7.25 (m, 3H), 7.09 (d, J=13.6Hz, 1H), 6.96 (d, J=9.0Hz, 1H), 6.06 (s, 2H), 3.73-2.90 (br m, 10H), and 2.65-2.54 (m, partially under DMSO, 1H), 2.46-2.18 (m, 4H), 1.63-1.42 (m, 4H). embodiment 44
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-{4-[5 '-(2-fluoro-phenyl)-octahydro-pentalene-2 '-yl)-piperazine-1-yl }-the benzonitrile maleic acid salt
MP:179-180.5 ℃. calculated value C 25H 27F 2N 3C 4H 4O 4: C, 66.53; H, 5.97; N, 8.03. measured value C, 66.62; H, 6.24; N, 7.98. embodiment 45
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-cyano group-4-{4-[5 '-(2-fluoro-phenyl)-octahydro-pentalene-2 '-yl)-piperazine-1-yl }-the benzonitrile maleic acid salt
MP:193-194 ℃. calculated value C 26H 27FN 4C 4H 4O 40.50H 2O:C, 66.78; H, 5.98; N, 10.38. measured value C, 66.99; H, 6.05; N, 10.34. embodiment 46
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-[4-(5 '-pyridine-2-octahydro-pentalene-2 '-yl)-piperazine-1-yl }-the benzonitrile dihydrochloride
MP:203-206 ℃. calculated value C 24H 27FN 42HClH 2O:C, 59.88; H, 6.49; N, 11.63. measured value: C, 59.55; H, 6.42; N, 11.47. embodiment 47
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-5-fluoro-2-{4-[5 '-(2-methoxyl group-phenyl)-octahydro-pentalene-2 '-yl)-piperazine-1-yl }-the pyrimidine maleic acid salt
MP:183.5-184.5 ℃. calculated value C 23H 29FN 4OC 4H 4O 4: C, 63.26; H, 6.49; N, 10.93 measured value C, 63.21; H, 6.71; N, 10.82. embodiment 48
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-{4-[5 '-(6-fluoro-2-oxo-2,3-dihydro-benzoglyoxaline-1-yl)-octahydro-pentalene-2 '-yl)-piperazine-1-yl }-benzonitrile diformazan sulphonyl hydrochlorate
MP:219-222 ℃. calculated value C 26H 27FN 5O2CH 4O 3S:C, 51.29; H, 5.38; N, 10.68. measured value C, 51.84; H, 5.57; N, 10.64.
Embodiment 49
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-{4-[5 '-(6-fluoro-dimethylbenzimidazole-1-yl)-octahydro-pentalene-2 '-yl)-piperazine-1-yl }-benzonitrile diformazan sulphonyl hydrochlorate
MP:＞260 ℃. calculated value C 27H 29F 2N 52CH 4O 3S0.50 H 2O:C, 52.56; H, 5.48; N, 10.57. measured value C, 5 embodiment 50
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-5-fluoro-2-[4-(3 ', 3 ' a, 4 ', 5 ', 6 ', 6 ' a '-six hydrogen spiral [isobenzofuran-1 (3H), 2 ' (1 ' H)-pentalene]-5 '-yl)-1-piperazine-1-yl]-pyrimidine
MP=186 ℃ of .NMR CDCl 3δ 8.20 (s, 2H), 7.25-7.17 (m, 4H), 7.12-7.09 (m, 1H), 5.00 (s, 2H), 3.79-3.71 (m, 4H), 2.72-2.44 (m, 7H), 2.20-2.13 (m, 2H), 2.17-1.93 (m, 2H), 1.69-1.67 (s, 2H). embodiment 51
(2 ' β, 3 ' α β, 5 ' α, 6 ' α β)-5-fluoro-2-[4-(3 ', 3 ' a, 4 ', 5 ', 6 ', 6 ' a-, six hydrogen spirals [isobenzofuran-1 (3H), 2 ' (1 ' H)-pentalene]-5 '-yl)-1-piperazine-1-yl]-pyrimidine
MP:186-187 ℃ of .NMR CDCl 3δ 8.18 (s, 2H), 7.26-7.10 (m, 3H), 7.08-7.06 (m, 1H), 5.00 (s, 2H), and 3.78-3.76 (br s, 4H), 2.78-2.73 (m, 2H), 2.66-2.54 (m, 5H), 2.32-2.22 (m, 4H), 1.74-1.69 (m, 2H), 1.38-1.29 (m, 2H). embodiment 52
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-1-phenyl-4-(3,3 ', 3 ' a, 4,4 ', 5 ', 6 ', 6 ' a-, six hydrogen spirals [2H-1-cumarone-2,2 ' (1 ' H)-pentalene]-5 '-yl]-5 '-yl)-the piperazine maleic acid salt
MP:200-201 ℃. calculated value C 26H 30N 2O 2C 4H 4O 4: C, 69.48; H, 6.61; N, 5.40. measured value C, 69.48; H, 6.80; N, 5.44. embodiment 53
(2 ' β, 3 ' α β, 5 ' α, 6 ' α β)-1-phenyl-4-(3,3 ', 3 ' a, 4,4 ', 5 ', 6 ', 6 ' a-, six hydrogen spirals [2H-1-cumarone-2,2 ' (1 ' H)-pentalene]-5 '-yl]-5 '-yl)-1-piperazine maleic acid salt
MP:220-221 ℃. calculated value C 26H 30N 2O 2C 4H 4O 4: C, 69.48; H, 6.61; N, 5.40. measured value C, 69.28 embodiment 54
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-3-[5 '-(4-phenyl-Piperazine-1-yl)-octahydro-pentalene-2 '-yl]-1H-indoles maleic acid salt
MP:232-232.5 ℃ of calculated value C 26H 31N 3C 4H 4O 4: C, 71.83; H, 7.03; N, 8.38. measured value C, 71.57; H, 7.38; N, 8.31. embodiment 55
(2 ' α, 3 ' α β, 6 ' α β)-1-phenyl-4-(5 '-phenyl-1 ', 2 ', 3 ', 3 ' a, 4 ', 6 ' a-, six hydrogen-pentalene]-2 '-yl)-piperazine two maleic acid salts
MP:156-157 ℃. calculated value C 26H 30N 2O 22C 4H 4O 4: C, 66.65; H, 6.29; N, 4.86. measured value C, 66.27; H, 6.57; N, 5.00. embodiment 56
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-1-phenyl-4-(5 '-phenyl-octahydro-pentalene-2 '-yl)-the piperazine maleic acid salt
MP:217-218 ℃. calculated value C 24H 30N 2C 4H 4O 4: C, 72.70; H, 7.41; N, 6.06. measured value C, 72.28; H, 7.46; N, 6.01. embodiment 57
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-6-fluoro-2-methyl isophthalic acid-[5 '-(4-phenyl-Piperazine-1-yl)-octahydro-pentalene-2 '-yl)-1H benzoglyoxaline two maleic acid salts
MP:203-205 ℃. calculated value C 26H 31FN 42C 4H 4O 40.50H 2O:C, 61.90; H, 6.11; N, 8.49. measured value C, 61.96; H, 6.01; N, 8.58. embodiment 58
(2 ' α, 3 ' α β, 5 ' β, 6 ' α β)-1-[5 '-(4-fluoro-phenoxy group)-octahydro-pentalene-2 '-yl]-4-phenylpiperazine maleic acid salt
MP:177-178 ℃. calculated value C 24H 29FN 2OC 4H 4O 4: C, 67.72; H, 6.70; N, 5.64. measured value C, 67.33; H, 6.82; N, 5.62. embodiment 59
(2 ' α, 3 ' α β, 5 ' β, 6 ' α β)-2-[5 '-(4-phenyl-Piperazine-1-yl)-octahydro-pentalene-2 '-yl]-the isoindole maleic acid salt
MP:235.5-236 ℃. calculated value C 26H 29N 3O 2C 4H 4O 4: C, 67.78; H, 6.26; N, 7.90. measured value C, 67.71; H, 6.37; N, 7.94. embodiment 60
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-N-(2-{5 '-[4-(5-fluoro-pyrimidine-2-base)-piperazine-1-yl]-octahydro-pentalene-2 '-yl }-phenyl)-the ethanamide maleic acid salt
MP:211.5-212 ℃. calculated value C 24H 30FN 5OC 4H 4O 4: C, 62.33; H, 6.35; N, 12.98. measured value C, 62.07; H, 6.32; N, 12.87. embodiment 61
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-N-(2-{5 '-[4-(4-cyano group-3-fluoro-phenyl)-piperazine-1-yl]-octahydro-pentalene-2 '-yl }-phenyl)-the ethanamide maleic acid salt
MP:197-199 ℃. calculated value C 27H 31FN 4OC 4H 4O 4: C, 66.18; H, 6.27; N, 9.96. measured value C, 66.06; H, 6.20; N, 9.89. embodiment 62
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-{4-[5 '-(2-oxo-2,3-dihydro-benzoglyoxaline-1-yl)-octahydro-pentalene-2 '-yl]-piperazine-1-yl }-benzonitrile methylsulfonyl hydrochlorate
MP＞260 ℃. calculated value C 26H 28FN 5OCH 4O 3S0.50 H 2O:C, 58.89; H, 6.04; N, 12.72. measured value C, 59.01; H, 6.06; N, 12.71. embodiment 63
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-1-{5 '-[4-(5-fluoro-pyrimidine-2-base)-piperazine-1-yl]-octahydro-pentalene-2 '-yl }-1,3-dihydro-benzimidazolyl-2 radicals-ketone mesylate
MP＞260 ℃. calculated value C 23H 27FN 6OCH 4O 3S:C, 55.58; H, 6.04; N, 16.20.Found:C, 55.48; H, 5.87; N, 16.41. embodiment 64
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-{5 '-[4-(4-cyano group-3-fluoro-phenyl)-piperazine-1-yl]-octahydro-pentalene-2 '-yl }-the benzamide maleic acid salt
MP 198.5-200 ℃. calculated value C 26H 29FN 4OC 4H 4O 40.50 H 2O:C, 64.62; H, 6.15; N, 10.05. measured value C, 64.84; H, 6.01; N, 10.03. embodiment 65
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-N-[5 '-(4-phenyl-Piperazine-1-yl)-octahydro-pentalene-2 '-yl]-the benzamide maleic acid salt
MP:211-212.5 ℃. calculated value C 25H 31N 3OC 4H 4O 40.25H 2O:C, 68.28; H, 7.01; N, 8.23. measured value C, 68.17; H, 6.94; N, 8.18. embodiment 66
(2 ' α, 3 ' α β, 5 ' β, 6 ' α β)-2-fluoro-4-{4-[5 '-(4-fluoro-phenoxy group)-octahydro-pentalene-2 '-yl]-piperazine-1-yl }-the benzonitrile maleic acid salt
MP:192-193 ℃. calculated value C 25H 27F 2N 3OC 4H 4O 4: C, 64.55; H, 5.79; N, 7.79. measured value C, 64.50; H, 5.80; N, 7.71. embodiment 67
(2 ' α, 3 ' α β, 5 ' β, 6 ' α β)-5-fluoro-2-{4-[5 '-(4-fluoro-phenoxy group)-octahydro-pentalene-2 '-yl]-piperazine-1-yl }-the pyrimidine maleic acid salt
MP:192-194 ℃. calculated value C 22H 26F 2N 4OC 4H 4O 4: C, 60.46; H, 5.85; N, 10.85. measured value C, 60.30; H, 5.82; N, 10.78. embodiment 68
(2 ' α, 3 ' α β, 5 ' β, 6 ' α β)-2-fluoro-4-{4-[5 '-(2-oxo-2,3-dihydro-benzoglyoxaline-1-yl)-octahydro-pentalene-2 '-yl)-piperazine-1-yl }-the benzonitrile maleic acid salt
MP:170-177 ℃ of .NMR DMSO d 6δ 10.89 (s, 1H), 7.70 (t, J=8.4Hz, 1H), 7.30-7.23 (m, 1H), 7.11 (d, J=13.9Hz, 1H), 7.04-6.94 (m, 4H), 6.06 (s, 2H), 4.97-4.82 (m, 1H), 3.62-2.80 (br m, 10H), 2.75-2.63 (m, 2H), 2.60-2.50 (m partially under DMSOpeak, 1H), 2.48-2.36 (m, 2H), 1.60 (dd, J 1=12.4Hz, J 2=6.6Hz, 2H), 1.58-1.34 (m, 2H). embodiment 69
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-{4-[5 '-(3-methoxyl group-phenyl)-octahydro-pentalene-2 '-yl]-piperazine-1-yl }-the benzonitrile maleic acid salt
MP:169-170 ℃. calculated value C 26H 30FN 3OC 4H 4O 4: C, 67.27; H, 6.40; N, 7.85. measured value C, 67.18; H, 6.52; N, 7.87. embodiment 70
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-{4-[5 '-(4-methoxyl group-phenyl)-octahydro-pentalene-2 '-yl]-piperazine-1-yl }-the benzonitrile maleic acid salt
MP:186-186.5 ℃. calculated value C 26H 30FN 3OC 4H 4O 40.25H 2O:C, 66.71; H, 6.44; N, 7.78. measured value C, 66.70; H, 6.60; N, 7.60. embodiment 71
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-[4-(5 '--tolyl-octahydro-pentalene-2 '-yl)-piperazine-1-yl]-the benzonitrile maleic acid salt
MP:198-198.5 ℃. calculated value C 26H 30FN 3C 4H 4O 4: C, 69.35; H, 6.60; N, 8.09. measured value C, 69.48; H, 6.74; N, 8.14. embodiment 72
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-[4-(5 '-right-tolyl-octahydro-pentalene-2 '-yl)-piperazine-1-yl]-the benzonitrile maleic acid salt
MP:194-195 ℃ of .NMR DMSO d 6δ 7.70 (t, J=8.5Hz, 1H), 7.16-7.09 (m, 5H), 6.96) d, J=8.7Hz, 1H), 6.06 (s, 2H), 3.75-2.85 (m, 11H), 2.55-2.43 (m, part is under the DMSO peak, 1H), 2.40-2.23 (m, Dan Feng @2.26,7H altogether), (m, 4H) embodiment 73 for 1.63-1.32
(2 ' α, 3 ' α β, 5 ' β, 6 ' α β)-1-[5 '-(4-fluoro-phenoxy group)-octahydro-pentalene-2 '-yl]-4-phenyl-Piperazine maleic acid salt
MP:174-175 ℃. calculated value C 24H 29FN 2OC 4H 4O 4: C, 67.72; H, 6.70; N, 5.64 measured value C, 67.82; H, 6.83; N, 5.59. embodiment 74
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-[4-(5 '-neighbour-tolyl-octahydro-pentalene-2 '-yl)-piperazine-1-yl]-the benzonitrile maleic acid salt
MP:198-199 ℃. calculated value C 26H 30FN 3C 4H 4O 4: C, 69.35; H, 6.60; N, 8.09. measured value C, 69.13; H, 6.69; N, 8.12. embodiment 75
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-1-phenyl-4-[5 '-(3-tetramethyleneimine-1-ylmethyl-phenyl)-octahydro-pentalene-2 '-yl)-piperazine two maleic acid salts
MP:163.5-164 ℃. calculated value C 29H 39N 32C 4H 4O 4: C, 67.15; H, 7.16; N, 6.35. measured value C, 66.81; H, 7.22; N, 6.27. embodiment 76
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-5-fluoro-2-[4-(3 ', 3 ' a, 4 ', 5 ', 6 ', 6 ' a-, six hydrogen-3 ' a, 6 ' a-dimethyl spiral [isobenzofuran-1 (3H), 2 ' (1 ' H)-pentalene]-5 '-yl)-1-piperazine-1-yl]-the pyrimidine maleic acid salt
MP:224.5-225 ℃. calculated value C 25H 31FN 4O C 4H 4O 40.25H 2O:C, 64.13; H, 6.59; N, 10.32. measured value C, 64.25; H, 6.68; N, 10.14. embodiment 77
(2 ' β, 3 ' α β, 5 ' α, 6 ' α β)-5-fluoro-2-[4-(3 ', 3 ' a, 4 ', 5 ', 6 ', 6 ' a-, six hydrogen-3 ' a, 6 ' a-, two-methyl spiral [isobenzofuran-1 (3H), 2 ' (1 ' H)-pentalene]-5 '-yl)-the 1-piperazine]-the pyrimidine maleic acid salt
MP:222-223 ℃ of .NMR DMSO.d 6. δ 8.58 (s, 2H), 7.34-7.30 (m, 1H), 7.28-7.25 (m, 3H) .6.04 (s, 2H), 4.94 (s, 2H), and 3.65-2.75 (br m, 9H), 2.20-2.12 (m, 2H), 1.94 (ABquartet, Δ=37.8Hz, J=13.2Hz, 4H), 1.54 (br t, J=11.7Hz, 2H), 1.21 (s, 6H). embodiment 78
(2 ' α, 3 ' α β, 5 ' β, 6 ' α β)-4-{4-[5 '-(1,3-dioxo-1,3-dihydro-isoindole-2-yl)-octahydro-pentalene-2 '-yl)-piperazine-1-yl }-2-fluoro-benzonitrile maleic acid salt
MP:224-224.5 ℃. calculated value C 27H 27FN 4O 2C 4H 4O 4: C, 64.80; H, 5.44; N, 9.75. measured value C, 64.85; H, 5.56; N, 9.74. embodiment 79
(2 ' α, 3 ' α β, 5 ' β, 6 ' α β)-2-{5 '-[4-(5-fluoro-pyrimidine-2-base)-piperazine-1-yl]-octahydro-pentalene-2 '-yl }-isoindole-1,3-diketone maleic acid salt
MP:241.5-242 ℃. calculated value C 24H 26FN 5O 2C 4H 4O 4: C, 60.97; H, 5.48; N, 12.70. measured value C, 60.66; H, 5.55; N, 12.44. embodiment 80
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-[4-(3,3 ', 3 ' a, 4,4 ', 5 ', 6 ', 6 ' a-, six hydrogen-spiral [2H-6-fluoro-1-cumarone-2,2 ' (1 ' H)-pentalene]-5 '-yl]-5 '-yl)-the 1-piperazine]-the benzonitrile maleic acid salt
MP:219-220 ℃. calculated value C 24H 26F 2N 4O 2C 4H 4O 40.50H 2O:C, 59.46; H, 5.55; N, 9.90. measured value C, 59.86; H, 5.70; N, 9.40. embodiment 81
(2 ' β, 3 ' α β, 5 ' α, 6 ' α β)-2-fluoro-4-[4-(3,3 ', 3 ' a, 4,4 ', 5 ', 6 ', 6 ' a-, six hydrogen-spiral [2H-6-fluoro-1-cumarone-2,2 ' (1 ' H)-pentalene]-5 '-yl]-5 '-yl)-1-piperazine-1-yl]-the benzonitrile maleic acid salt
MP:216.5-217 ℃. calculated value C 24H 26F 2N 4O 2C 4H 4O 4: C, 60.43; H, 5.43; N, 10.07. measured value C, 60.39; H, 5.47; N, 9.90. embodiment 82
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-5-fluoro-2-[4-(5 '-neighbour-tolyl-octahydro-pentalene-2 '-yl)-piperazine-1-yl]-the pyrimidine maleic acid salt
MP:204-205 ℃. calculated value C 23H 29FN 4C 4H 4O 4: C, 65.31; H, 6.70; N, 11.28. measured value C, 65.38; H, 6.77; N, 11.32. embodiment 83
(2 ' β, 3 ' α β, 5 ' α, 6 ' α β)-1-{5 '-[4-(4-fluoro-phenyl)-piperazine-1-yl]-octahydro-pentalene-2 '-yl }-1,3-dihydro-benzimidazolyl-2 radicals-ketone maleic acid salt
MP:217-218 ℃. calculated value C 25H 29FN 4OC 4H 4O 4: C, 64.91; H, 6.20; N, 10.44. measured value C, 64.57; H, 6.28; N, 10.18. embodiment 84
(2 ' β, 3 ' α β, 5 ' α, 6 ' α β)-2-[5 '-(4-phenyl-Piperazine-1-yl]-octahydro-pentalene-2 '-Ji oxygen base]-1H-benzoglyoxaline maleic acid salt
MP:161-162 ℃. calculated value C 25H 30N 4OC 4H 4O 4: C, 67.16; H, 6.61; N, 10.80. measured value C, 67.05; H, 6.66; N, 10.59. embodiment 85
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-5-chloro-2-{4-[5 '-(2-methoxyl group-phenyl)-octahydro-pentalene-2 '-yl]-piperazine-1-yl }-the pyrimidine maleic acid salt
MP:199.5-200 ℃. calculated value C 23H 29ClN 4OC 4H 4O 4: C, 61.30; H, 6.29; N, 10.59. measured value C, 61.05; H, 6.31; N, 10.83. embodiment 86
(2 ' α, 3 ' α β, 5 ' α, 6 ' α β)-5-chloro-2-[4-(5 '-neighbour-tolyl-octahydro-pentalene-2 '-yl)-piperazine-1-yl]-the pyrimidine maleic acid salt
MP:200-200.5 ℃. calculated value C 23H 29ClN 4C 4H 4O 4: C, 63.21; H, 6.48; N.10.92. measured value C, 62.97; H, 6.33; N, 11.29. embodiment 87
(2 ' β, 3 ' α β, 5 ' α, 6 ' α β)-2-{5 '-[4-(3,4-two fluoro-phenyl)-piperazine-1-yl]-octahydro-pentalene-2 '-yl }-isoindole-1,3-diketone maleic acid salt
MP:221.5-222 ℃. calculated value C 26H 27F 2N 3O 2C 4H 4O 4: C, 63.48; H, 5.51; N, 7.46. measured value C, 63.28; H, 5.51; N, 7.64. embodiment 88
(2 ' β, 3 ' α β, 5 ' α, 6 ' α β)-2-{5 '-[4-(4-fluoro-phenyl)-piperazine-1-yl]-octahydro-pentalene-2 '-yl }-isoindole-1,3-diketone maleic acid salt
MP:209-210 ℃. calculated value C 26H 28FN 3O 2C 4H 4O 40.50H 2O:C, 64.51; H, 5.95; N, 7.52. measured value C, 64.47; H, 5.91; N, 7.66. embodiment 89
(2 ' β, 3 ' α β, 5 ' α, 6 ' α β)-1-{5 '-[4-(3,4-two fluoro-phenyl)-piperazine-1-yl]-octahydro-pentalene-2 '-yl }-1,3-dihydro-benzimidazolyl-2 radicals-ketone maleic acid salt
MP:201-202 ℃. calculated value C 25H 28F 2N 4OC 4H 4O 40.50H 2O:C, 61.80; H, 5.90; N, 9.94. measured value C, 62.10; H, 5.80; N, 9.56

Claims (21)

1. the compound of formula I
Figure A9880783100021
Or the acceptable salt of its medicine, wherein dotted line is represented a selectable pair of key;
A is 0 or 1, and wherein when a was 0, X formed optional two keys with the carbon of adjacency V;
V is CHR 10, R wherein 10Be hydrogen or (C 1-C 6) alkyl;
T is nitrogen or CH;
X is nitrogen or CR 11, R wherein 11Be hydrogen, (C 1-C 6) alkyl, (C 1-C 6) alkoxyl group, hydroxyl itself or cyano group;
Each is nitrogen or CR independently for Y and Z 12, R wherein 12Be hydrogen, chlorine, bromine, trifluoromethyl, trifluoromethoxy, cyano group, (C 1-C 6) alkoxyl group or (C 1-C 6) alkyl;
R 1Be hydrogen, fluorine, chlorine, bromine, trifluoromethyl, trifluoromethoxy, cyano group, or (C 1-C 6) alkyl;
R 2, R 6, R 7, R 8And R 9Be independently selected from hydrogen, fluorine, chlorine, bromine, trifluoromethyl, trifluoromethoxy, cyano group, (C 1-C 6) alkoxyl group or (C 1-C 6) alkyl;
R 3And R 4Be hydrogen or (C independently 1-C 6) alkyl; With
R 5Be hydrogen, (C 1-C 6) alkoxyl group, trifluoromethyl, cyano group, (C 1-C 6) alkyl or R 13CO-, wherein R 13Be amino, (C 1-C 6) alkylamino, ((C 1-C 6) alkyl) 2Amino, (C 1-C 6) alkyl, (C 1-C 6) aryl;
Or when a is 1, R 1And R 10Carbon that can be coupled forms the compound of following formula together:
Figure A9880783100022
Wherein dotted line is represented a selectable key;
T, X, Y, Z, R 2, R 3, R 4, R 5, R 6, R 7, R 8And R 9Definition as above;
B is 0 or 1; With
Each is CH independently for A and B, CH 2, oxygen, sulphur, NH or nitrogen;
Condition is when X is nitrogen, does not have optional two keys between X and the V; With
Condition is when b is 0, does not have optional two keys between A and the B; With
Condition is when b is 1, and A and B can not be oxygen or sulphur.
2. the compound of claim 1, wherein X is a nitrogen.
3. the compound of claim 1, wherein Y and Z each be CR 12, R wherein 12Be hydrogen or fluorine.
4. the compound of claim 1, wherein R 2Be hydrogen, fluorine or chlorine.
5. the compound of claim 1, wherein R 3, R 4And R 5Be hydrogen.
6. the compound of claim 1, wherein R 7It is fluorine or chlorine.
7. the compound of claim 1, wherein R 9Be fluorine, chlorine, bromine or alkoxyl group.
8. the compound of claim 1, wherein X is a nitrogen; Each is CR for Y and Z 12Compound, R wherein 12Be hydrogen or fluorine; R 2Be hydrogen, fluorine or chlorine; R 3, R 4And R 5Be hydrogen; R 7It is fluorine or chlorine; R 7Be fluorine, chlorine, bromine or alkoxyl group.
9. the compound of claim 1, wherein said compound is selected from:
2-[4-(3-trifluoromethyl-phenyl)-piperazine-1-ylmethyl]-the 1H-indoles;
5-fluoro-2-[4-(3-trifluoromethyl-phenyl)-piperazine-1-ylmethyl]-the 1H-indoles;
5-fluoro-2-[4-(4-methyl fluoride-phenyl)-piperazine-1-ylmethyl]-the 1H-indoles;
5-fluoro-2-[4-(4-methyl fluoride-phenyl)-piperazine-1-ylmethyl]-the 1H-indoles;
5-fluoro-2-(4-pyridine-2-base-piperazine-1-ylmethyl]-the 1H-indoles;
2-[4-(6-chloro-pyridazine-3-yl)-piperazine-1-ylmethyl]-5-fluoro-1H-indoles;
5-fluoro-2-(4-[5 '-fluorine] pyridine-2-base-piperazine-1-ylmethyl]-the 1H-indoles;
2-(4-pyridine-2-base-piperazine-1-ylmethyl)-1H-indoles;
5-fluoro-2-(4-pyridine-2-base-piperazine-1-ylmethyl]-the 1H-azaindole; With
2-[4-(4-fluoro-phenyl)-piperazine-1-ylmethyl]-the 1H-azaindole.
10. method for the treatment of the Mammals disorders of dopamine system comprises and gives said Mammals with the D4 dopamine 2 receptor alternative cpd or the acceptable salt dispenser of its medicine of formula I of effectively treating a certain amount of claim 1 of this disorder.
11. the method for claim 10, wherein this disorders of dopamine system comprises psychosis, mobility disorder, gastrointestinal dysfunction, chemical abuse disease, chemical dependence syndrome, substance abuse disease, blood vessel and cardiovascular disorder, eyes disorder and sleep disordered.
12. method for the treatment of the Mammals disorders of dopamine system, comprise the D4 dopamine 2 receptor alternative cpd of formula I of a certain amount of claim 1 that will effectively treat this disorder or the acceptable salt of its medicine, in conjunction with one or more D1, D2, D3 or D5 dopamine-receptor stimulant dispenser together give said Mammals.
13. the method for claim 12, wherein this disorders of dopamine system comprises psychosis, mobility disorder, gastrointestinal dysfunction, chemical abuse disease, chemical dependence syndrome, substance abuse disease, blood vessel and cardiovascular disorder, eyes disorder and sleep disordered.
14. the method for claim 11, wherein psychosis comprises alternating insanity, incoherence of speech and schizoaffective psychosis.
15. the method for claim 11, wherein the mobility disorder comprises the extrapyramidal side effect of tranquilizer generation, the pernicious syndromes of tranquilizer, tardy dyskinesia, Tourette's syndrome syndromes, Parkinson's disease, Huntington.
16. the method for claim 11, wherein gastrointestinal dysfunction comprises hydrochloric acid in gastric juice secretin or vomiting.
17. the method for claim 11, its medium vessels and cardiovascular disorder comprise congestive heart failure and hypertension.
18. a pharmaceutical composition for the treatment of the Mammals disorders of dopamine system comprises and gives said Mammals with the D4 dopamine 2 receptor alternative cpd of formula I or the acceptable salt dispenser of its medicine of effectively treating a certain amount of claim 1 of this disorder.
19. the pharmaceutical composition of claim 18, wherein this disorders of dopamine system comprises psychosis, mobility disorder, gastrointestinal dysfunction, chemical abuse disease, chemical dependence syndrome, substance abuse disease, blood vessel and cardiovascular disorder, eyes disorder and sleep disordered.
20. pharmaceutical composition for the treatment of the Mammals disorders of dopamine system, comprise the D4 dopamine 2 receptor alternative cpd of a certain amount of formula I that will effectively treat this disorder or the acceptable salt of its medicine, in conjunction with one or more D1, D2, D3 or D5 dopamine-receptor stimulant dispenser together give said Mammals.
21. the pharmaceutical composition of claim 20, wherein this disorders of dopamine system comprises psychosis, mobility disorder, gastrointestinal dysfunction, chemical abuse disease, chemical dependence syndrome, substance abuse disease, blood vessel and cardiovascular disorder, eyes disorder and sleep disordered.
CN98807831A 1997-08-15 1998-08-05 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives Pending CN1265660A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5576497P 1997-08-15 1997-08-15
US60/055,764 1997-08-15

Publications (1)

Publication Number Publication Date
CN1265660A true CN1265660A (en) 2000-09-06

Family

ID=22000003

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98807831A Pending CN1265660A (en) 1997-08-15 1998-08-05 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives

Country Status (30)

Country Link
EP (1) EP1003739A2 (en)
JP (1) JP2002536291A (en)
KR (1) KR20010022507A (en)
CN (1) CN1265660A (en)
AP (1) AP9801321A0 (en)
AR (1) AR017019A1 (en)
AU (1) AU8457298A (en)
BG (1) BG104069A (en)
BR (1) BR9811557A (en)
CA (1) CA2297486C (en)
CO (1) CO4960656A1 (en)
DZ (1) DZ2583A1 (en)
EA (1) EA200000023A1 (en)
HR (1) HRP980441A2 (en)
HU (1) HUP0003425A3 (en)
ID (1) ID23803A (en)
IL (1) IL133960A0 (en)
IS (1) IS5336A (en)
MA (1) MA24632A1 (en)
NO (1) NO20000722D0 (en)
OA (1) OA11286A (en)
PA (1) PA8457001A1 (en)
PE (1) PE106299A1 (en)
PL (1) PL338947A1 (en)
SK (1) SK1352000A3 (en)
TN (1) TNSN98151A1 (en)
TR (1) TR200000414T2 (en)
UY (1) UY25144A1 (en)
WO (1) WO1999009025A2 (en)
ZA (1) ZA987304B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101291925B (en) * 2005-10-26 2013-04-10 詹森药业有限公司 Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021834A1 (en) * 1997-10-27 1999-05-06 Neurosearch A/S Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
EP0953567A3 (en) 1998-04-29 2003-04-02 Pfizer Products Inc. Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity
SK11072002A3 (en) * 1999-12-30 2003-03-04 H. Lundbeck A/S Halo-substituted 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives, pharmaceutical composition containing the same and use thereof
GB0017952D0 (en) * 2000-07-22 2000-09-13 Univ Manchester Treatment of dyskinesia
EP1177792A3 (en) 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders
WO2002072548A2 (en) * 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
US7504426B2 (en) 2002-09-06 2009-03-17 Janssen Pharmaceutica N.V. Heterocyclic compounds
WO2004108671A1 (en) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
WO2005095338A1 (en) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
US7618980B2 (en) 2004-07-14 2009-11-17 Bristol-Myers Squibb Company Pyrrolo(oxo)quinolines as 5HT ligands
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Fast Dissociating Dopamine 2 Receptor Antagonists
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Fast -Dissociating Dopamine 2 Receptor Antagonists
RS52518B (en) 2007-04-23 2013-04-30 Janssen Pharmaceutica N.V. 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
EP2148879B1 (en) 2007-04-23 2012-11-28 Janssen Pharmaceutica, N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
CN102159554B (en) 2008-07-03 2014-09-24 詹森药业有限公司 Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists
HUE033768T2 (en) 2008-07-31 2017-12-28 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
EP3686196B1 (en) * 2017-09-20 2024-06-12 Hangzhou Innogate Pharma Co., Ltd. Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor
CN115427404A (en) * 2020-04-22 2022-12-02 艾尼莫生物科技公司 Collagen 1 translation inhibitors and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB944443A (en) * 1959-09-25 1900-01-01
DE69217224T2 (en) * 1991-07-03 1997-06-05 Pharmacia & Upjohn Co., Kalamazoo, Mich. SUBSTITUTED INDOLE AS ANTI-AIDS PHARMACEUTICAL PREPARATIONS
JPH05255089A (en) * 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd Antiviral agent
WO1994010162A1 (en) * 1992-10-23 1994-05-11 Merck Sharp & Dohme Limited Dopamine receptor subtype ligands
AU6215594A (en) * 1993-03-18 1994-10-11 Merck Sharp & Dohme Limited Indole derivatives as dopamine d4 antagonists
GB9305644D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
US5814644A (en) * 1993-04-15 1998-09-29 Merck Sharp & Dohme, Ltd. Indole derivatives as dopamine D4 antagonists
DE4414113A1 (en) * 1994-04-22 1995-10-26 Merck Patent Gmbh 3-indolylpiperidines
TW406075B (en) * 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
ZA968661B (en) * 1995-11-17 1998-04-14 Upjohn Co Oxazolidinone antibacterial agent with tricyclic substituents.
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101291925B (en) * 2005-10-26 2013-04-10 詹森药业有限公司 Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists

Also Published As

Publication number Publication date
EP1003739A2 (en) 2000-05-31
IL133960A0 (en) 2001-04-30
IS5336A (en) 2000-01-11
ZA987304B (en) 2000-02-14
ID23803A (en) 2000-05-11
PL338947A1 (en) 2000-12-04
DZ2583A1 (en) 2003-02-22
PE106299A1 (en) 1999-11-02
WO1999009025A2 (en) 1999-02-25
PA8457001A1 (en) 2000-09-29
TNSN98151A1 (en) 2005-03-15
AP9801321A0 (en) 2000-02-14
WO1999009025A3 (en) 1999-04-15
BG104069A (en) 2001-05-31
HUP0003425A3 (en) 2002-02-28
CA2297486A1 (en) 1999-02-25
UY25144A1 (en) 2000-12-29
HRP980441A2 (en) 1999-04-30
HUP0003425A2 (en) 2001-10-28
KR20010022507A (en) 2001-03-15
OA11286A (en) 2003-10-22
CA2297486C (en) 2005-05-03
SK1352000A3 (en) 2000-08-14
CO4960656A1 (en) 2000-09-25
AU8457298A (en) 1999-03-08
MA24632A1 (en) 1999-04-01
NO20000722L (en) 2000-02-14
TR200000414T2 (en) 2000-08-21
NO20000722D0 (en) 2000-02-14
AR017019A1 (en) 2001-08-22
EA200000023A1 (en) 2000-08-28
JP2002536291A (en) 2002-10-29
BR9811557A (en) 2000-08-22

Similar Documents

Publication Publication Date Title
CN1265660A (en) 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives
CN1036456C (en) Amino-substituted pyrazoles
CN1263755C (en) Pyrazolopyridine derivatives as selective COX-2 inhibitors
CN1034939C (en) New compounds
CN1092643C (en) Certain aminomethyl phenylidazole derivatives, a new class of dopamine receptor subtype specific ligands
CN1113236A (en) Non-peptidyl tachykinin receptor antagonists
CN1262678A (en) Triazole compounds and use thereof as dopamine-D3-ligands
CN1602196A (en) Ureas of 2-aminobenzothiazoles as adenosine modulators
CN1265591A (en) Coumpound
CN1098098A (en) Bridged piperazine derivatives
CN1124960A (en) Indole derivatives as 5-HT1A and/or 5-HT2 ligands
CN1045781A (en) N-(3-hydroxy-4-piperidinyl base) (Dihydrobenzofuranes, dihydro-2H-chromene or dihydrobenzo two  English) carboxamides derivatives
CN1133043A (en) Bicyclic aromatic compounds as therapeutic agents
CN1009831B (en) Process for preparing heterocycle-oxo-2,3-diazanaphthyl-acetic acid
CN1653067A (en) Carbazole derivatives and their use as NPY5 receptor antagonists
CN1625556A (en) Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
CN1492863A (en) Heterocyclylalkylindole or azaindole compounds as 5-hydroxytryptamine-6 ligands
CN1871242A (en) 3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety
CN87103504A (en) Heterocyclic carboxamide
CN1516580A (en) Sulfonamides
CN1437596A (en) Phenylpiperazinyl derivatives
CN86102349A (en) Preparation N-[(4-piperidyl) alkyl] the bicyclic condensed  azoles that replaces and the method for thiazole amine
CN1050122C (en) Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them
CN1205704A (en) 2,7-substituted octahydro-pyrrolo (1,2-A) pyrazine derivatives
CN1272842A (en) 2-acylaminopropanamines as tachykinin receptor antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication